Stingray Therapeutics develops next-generation immunotherapies that harness the full potential of the immune system to target and eliminate cancer cells. Their approach addresses the limitations of traditional cancer treatments by enhancing immune response, aiming to improve patient outcomes across various cancer types.
Funding
$8.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments often fail to fully harness the body's immune system to effectively target and eliminate cancer cells, leading to limited efficacy and potential for recurrence. Current immunotherapies may not stimulate a sufficiently robust or targeted immune response across diverse cancer types.
Solution
Stingray Therapeutics is developing a novel class of immunotherapies designed to enhance the immune system's ability to recognize and destroy cancer cells. Their approach aims to overcome the limitations of existing treatments by stimulating a more comprehensive and targeted immune response. By fully activating the immune system, Stingray Therapeutics seeks to improve patient outcomes across a broad spectrum of cancers.
Target Audience
The primary target audience includes cancer patients, oncologists, and researchers seeking more effective and innovative immunotherapeutic options.
Features
- Next-generation immunotherapy platform designed to fully engage the immune system.
- Focus on stimulating a robust and targeted immune response against cancer cells.
- Aims to improve efficacy across various cancer types.